Apurv Puri

Apr 15, 2024 | outsourcedpharma.com | Diane McCarthy |Li Jing |Andrea Rabellino |Apurv Puri |Louis Garguilo

Four Steps To Identifying The CDMO Proposal Worth SigningTransparency and communication are essential to the success of a manufacturing partnership. If a CDMO is unwilling to have frank conversations during the proposal phase, that’s likely a red flag. The right partner’s team will help you make educated choices while ensuring quality, reasonable costs, and timeline efficiency. When characterizing PQAs, the multi-attribute method offers a one-stop shop for analysis.

Mar 18, 2024 | bioprocessonline.com | Mark Witcher |Apurv Puri |Pharmatech Associates

In this presentation from the February 2024 OPCU event, Mabion, a biologics CDMO with end-to-end services focusing on recombinant proteins development and production, showcases their new installations in upstream development, bioreactors, and downstream development and fill finish. This state-of-the-art EU-GMP-certified facility is staffed by a team of 250 professionals and as of 2023 is focused solely on providing CDMO services to its clients. Watch now.

Sep 18, 2023 | wateronline.com | Apurv Puri |Pharmatech Associates

By Apurv Puri, Principal Consultant, Pharmatech Associates VIEW THE WHITE PAPER! Get unlimited access to: Trend and Thought Leadership Articles Case Studies & White Papers Extensive Product Database Members-Only Premium Content Welcome Back! Please Log In to Continue. X Enter your credentials below to log in. Not yet a member of Water Online? Subscribe today.

Sep 18, 2023 | bioprocessonline.com | Pharmatech Associates |Apurv Puri

By Apurv Puri, Principal Consultant, Pharmatech Associates In biologics, viral vector, and cell therapy products, CO2 levels can impact metabolic fluxes responsible for driving productivities of cell systems and specific growth rates. CO2 is a process parameter directly linked to cell health, specific growth rates, metabolic states, and driving productivities of cell systems, and inconsistent CO2 levels can lead to a potentially adverse safety and efficacy risk profile in drug products.